Last reviewed · How we verify

NCT02862392: SCOLEVOL

Predictive Progressive Factors of Adolescent Idiopathic Scoliosis

Completed Last updated 10 September 2025
What this trial tests

trial in Scoliosis in 95 participants. Completed in 4 December 2024.

Timeline
15 March 2017
Primary endpoint
4 December 2024
4 December 2024

Quick facts

Lead sponsorLille Catholic University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment95
Start date15 March 2017
Primary completion4 December 2024
Estimated completion4 December 2024
Sites4 locations across France

Conditions studied

Sponsor

Lille Catholic University

Who can join

Adults 11 to 14, female only, with Scoliosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The hypothesis of this study is that progressive AIS is characterized by a disorder of orthostatic postural control. The analysis and the treatment of posturographic signal on computerized integrate force plates, coupled to clinical and radiographic examinations, could highlight predictive and reliable factors at the moment of diagnosis. Thus, it could help the clinician in his therapeutic approach, based on the postural control improvement (individualized prescription in kinesitherapy, better adaptation to orthopedic treatments by corset). This method is non-invasive, without side effects, fast and achievable in routine care at the moment of the diagnosis of AIS.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Scoliosis

Currently open trials in the same condition.

Other Lille Catholic University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02862392.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing